[Form 4] Edwards Lifesciences Corp Insider Trading Activity

Rhea-AI Filing Summary

Andrew M. Dahl, SVP and Corporate Controller of Edwards Lifesciences (EW), reported a sale of 262 shares of common stock on 09/13/2025 at a price of $77.57 per share. After the reported transaction, the filing shows beneficial ownership of 7,926.9331 shares. The form notes this filing reflects changes in beneficial ownership only and includes a quarterly acquisition under the issuer's Employee Stock Purchase Plan.

Insights

Financial Analyst

TL;DR: Insider sale was small relative to total holdings and appears routine.

The reported disposition of 262 shares at $77.57 represents a minor reduction in the reporting person's position versus the remaining 7,926.9331 shares. The filing explicitly states it reflects changes in beneficial ownership only and references routine Employee Stock Purchase Plan activity. There is no additional financial data or indicators of company-wide change in this Form 4.

Corporate Governance Expert

TL;DR: Disclosure meets Section 16 reporting requirements; transaction appears procedural.

The Form 4 identifies the reporting person, role (SVP, Corporate Controller), transaction date (09/13/2025), transaction type (disposition), shares sold (262) and price ($77.57). The remarks note ESPP quarterly acquisition activity. There are no indications of unusual trading patterns or material governance events in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dahl Andrew M.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Corporate Controller

3. Date of Earliest Transaction (Month/Day/Year)
09/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/13/2025		F		262	D	$77.57	7,926.9331	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

	Linda J. Park, Attorney-in-Fact	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Edwards Lifesciences insider Andrew M. Dahl report on Form 4?

The Form 4 reports a disposition of 262 shares of Edwards Lifesciences common stock on 09/13/2025 at $77.57 per share.

How many Edwards Lifesciences shares does the reporting person own after the transaction?

The filing shows beneficial ownership of 7,926.9331 shares following the reported transaction.

What is Andrew M. Dahl's role at Edwards Lifesciences as shown on the filing?

The filing lists Andrew M. Dahl as an Officer with the title SVP, Corporate Controller.

Does the Form 4 mention any employee plan activity?

Yes. The remarks state the Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

When was the Form 4 signed and filed?

The signature block shows execution by attorney-in-fact Linda J. Park and is dated 09/15/2025.